Immunic stock, Immunic

Immunic stock: Q3 loss widens ahead of December trial data

Published on 11/17/2026 at 22:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Immunic stock faces a larger quarterly loss as investors await December results from two pivotal multiple sclerosis trials. Cash runway extends into late 2027.

Quarterly loss and trial timeline

  • Immunic reported a third-quarter net loss of 42.3 million US dollars, compared with 25.6 million US dollars a year earlier.
  • The company expects top-line results from its ENSURE-1 and ENSURE-2 Phase 3 trials in December 2026.
  • Immunic expects its cash and cash equivalents to fund operations into late 2027 under its current plan.
Immunic stock, Immunic, third-quarter results, multiple sclerosis, ENSURE trials, biotechnology, Illustration mit AI erstellt.

Immunic reported a wider third-quarter loss on November 13 as the biotechnology company moved closer to pivotal multiple sclerosis trial results expected in December. The company said its fully enrolled ENSURE-1 and ENSURE-2 Phase 3 studies of vidofludimus calcium remain on track to deliver top-line data during the month, according to a PR Newswire release from Immunic.

Net loss for the three months ended September 30 reached 42.3 million US dollars, or 0.99 US dollars per share, compared with a loss of 25.6 million US dollars, or 1.32 US dollars per share, in the year-earlier quarter. Operating expenses rose to 43.4 million US dollars from 26.0 million US dollars, including 13.9 million US dollars of non-cash charges, primarily stock compensation.

December readout sets next milestone

ENSURE-1 and ENSURE-2 randomized 1,121 and 1,100 patients, respectively, at more than 100 sites in 15 countries. If the results are positive, Immunic plans to submit a US New Drug Application in mid-2027 and targets potential regulatory approval in 2028.

The company is also preparing the Phase 3 PROTECT-MS trial in progressive multiple sclerosis, with first-patient enrollment expected in the first half of 2027. Immunic reported cash and cash equivalents of 132.0 million US dollars at September 30 and expects those funds to support operations into late 2027 under its current operating plan.

Immunic stock traded at 6.64 euros on Lang & Schwarz at 22:16 CET on Tuesday, November 17, 2026.

Immunic company details

  • Company: Immunic, Inc.
  • Ticker: IMUX
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 6.64 euros at 22:16 CET on November 17, 2026

US biotechnology stocks trade against a wider Nasdaq backdrop in the Nasdaq Composite market environment.

Disclaimer...
en | boerse | 70528710 |